Loading
HLX11 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, aimed at HER2.
HLX11 is a monoclonal antibody developed by Shanghai Henlius Biotech. Its target is HER2 (the sponsor names HER2). The sponsor states: A recombinant anti-HER2 domain II humanised monoclonal antibody developed as a biosimilar to pertuzumab (EU-Perjeta), given with trastuzumab and docetaxel in neoadjuvant HER2-positive breast cancer. ClinicalTrials.gov describes the intervention as: Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV, followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophos. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05346224 (A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT05346224, plans to enrol 900 participants with primary completion was scheduled for 2024-05-15 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A recombinant anti-HER2 domain II humanised monoclonal antibody developed as a biosimilar to pertuzumab (EU-Perjeta), given with trastuzumab and docetaxel in neoadjuvant HER2-positive breast cancer. Connects to HER2.
1.HLX11 binds HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HLX11" OR ABSTRACT:"HLX11") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLX11, not a curated reading list.
Shares Shanghai Henlius Biotech, HER2-positive breast cancer and the tag pipeline.
Shares Shanghai Henlius Biotech, HER2, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Shanghai Henlius Biotech, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.